国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

交易中 10-21 09:57:34

15.810

+0.440

+2.86%

最高15.870	最低15.460	成交量104.19万
今开15.570	昨收15.370	日振幅2.67%
总市值493.43亿	流通市值212.14亿	总股本31.21亿
成交额1,634万	换手率0.08%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":15.81,"timestamp":1792547850237,"preClose":15.37,"halted":0,"volume":1041885,"delay":0,"changeRate":0.028627195836044325,"floatShares":1341810740,"shares":3121000000,"eps":2.29,"marketStatus":"交易中","change":0.44,"latestTime":"10-21 09:57:34","open":15.57,"high":15.87,"low":15.46,"amount":16335443,"amplitude":0.026675,"askPrice":15.81,"askSize":11200,"bidPrice":15.79,"bidSize":13600,"shortable":3,"etf":0,"ttmEps":2.620836,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1792555200000},"marketStatusCode":2,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":15.37,"dividendRate":0.049962,"openAndCloseTimeList":[[1792546200000,1792555200000],[1792558800000,1792569600000]],"volumeRatio":1.472562,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.2763,"impliedVolPercentile":0.5878},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"1104138210","title":"国药控股（01099）披露一致药业2026年前三季度业绩快报","url":"https://stock-news.laohu8.com/highlight/detail?id=1104138210","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104138210?lang=zh_cn&edition=full","pubTime":"2026-10-20 21:35","pubTimestamp":1792503335,"startTime":"0","endTime":"0","summary":"2026年10月20日，国药控股公告称，其在深圳证券交易所上市的附属公司国药集团一致药业股份有限公司发布了《2026年度前三季度业绩快报》。同期基本每股收益为1.56元；加权平均净资产收益率为5.03%，同比下降0.26个百分点。公司提醒投资者，本次快报数据为初步核算结果，未经会计师事务所审计，最终财务数据以2026年第三季度报告为准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154348538","title":"国药控股（01099）披露子公司国药一致前三季度业绩：前三季度净利9.52亿元，同比微降0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154348538","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154348538?lang=zh_cn&edition=full","pubTime":"2026-10-20 21:35","pubTimestamp":1792503335,"startTime":"0","endTime":"0","summary":"10月20日，国药控股发布公告，披露其控股子公司国药集团一致药业股份有限公司截至2026年9月30日止九个月的未经审计业绩快报。归属于上市公司股东的净利润为9.52亿元，同比下降0.48%；扣除非经常性损益后的归属于上市公司股东的净利润为9.45亿元，同比增长2.36%。基本每股收益为1.56元，与上年同期持平；加权平均净资产收益率为5.03%，同比下降0.26个百分点。基本每股收益0.57元，同比增长18.75%；加权平均净资产收益率1.82%，同比上升0.23个百分点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676994596","title":"国药控股(01099.HK)：国药一致第三季度实现归母净利润3.46亿元 同比增长18.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676994596","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676994596?lang=zh_cn&edition=full","pubTime":"2026-10-20 21:35","pubTimestamp":1792503325,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1197","01099","BK1515","BK1500","LU1115378108.SGD","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676454699","title":"国药控股(01099)：国药一致第三季度实现归母净利润3.46亿元 同比增长18.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676454699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676454699?lang=zh_cn&edition=full","pubTime":"2026-10-20 21:35","pubTimestamp":1792503325,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)公布，国药一致2026年前三季度实现营业总收入约550.66亿元，同比减少0.11%;归属于上市公司股东的净利润约9.52亿元，同比减少0.48%;基本每股收益1.56元。2026年第三季度，实现营业收入188.00亿元，同比增长2.57%;归属上市公司股东的净利润3.46亿元，同比增长18.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","000028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104105378","title":"国药控股（01099）公告子公司国药股份2026年三季报：单季净利润5.96亿元同比增9.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104105378","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104105378?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:05","pubTimestamp":1792490746,"startTime":"0","endTime":"0","summary":"2026年10月20日，国药控股股份有限公司披露其附属公司国药集团药业股份有限公司截至2026年9月30日止第三季度主要未经审计财务数据。报告期内，基本及稀释每股收益均为0.7906元，同比增长9.71%；加权平均净资产收益率为3.12%，较上年同期增加0.06个百分点。截至2026年9月30日，国药股份总资产为368.13亿元，较上年度末增长0.35%；归属上市公司股东的所有者权益为194.08亿元，较上年度末增长4.66%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193874754","title":"国药控股（01099）披露子公司国药股份2026年前三季度业绩：营收406.06亿元 净利14.76亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193874754","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193874754?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:00","pubTimestamp":1792490441,"startTime":"0","endTime":"0","summary":"2026年10月20日，国药控股公告披露，其A股上市附属公司国药集团药业股份有限公司发布了2026年第三季度报告。报告显示，国药股份今年前三季度经营保持增长，核心财务数据如下：。2026年前三季度实现营业收入406.06亿元，同比增长3.11%。实现归属于上市公司股东的净利润14.76亿元，同比下降1.07%。控股股东国药控股股份有限公司持有公司5.13亿股，占比54.72%。本次季报未经审计，国药股份董事会及全体董事对报告内容的真实性、准确性、完整性承担责任。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676661099","title":"国药控股(01099.HK)：国药股份(600511.SH)前三季度实现归母净利润约14.76亿元，同比减少1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676661099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676661099?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:59","pubTimestamp":1792490381,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01099","BK1515","BK1500","LU0640798160.USD","LU1115378108.SGD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187033023","title":"国药控股（01099）将于10月23日审议2026年第三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1187033023","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187033023?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:21","pubTimestamp":1792405273,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司（01099）董事会10月19日发布公告称，公司董事会会议定于2026年10月23日（星期五）召开，届时将审议并批准公司及其附属公司截至2026年9月30日止三个月的未经审计季度业绩。\n公告显示，本次董事会会议议程之一即为审议2026年第三季度财务业绩报告。公司董事长晋斌代表董事会签署了该份公告。\n根据公告，国药控股现任董事会成员包括：执行董事连万勇、杨秉华；非执行董事晋斌、陈启宇、祖敬、邢永刚、马跃、陈玉卿、文德鏞、李瑩；独立非执行董事李培育、吴德龙、俞卫锋、石晟昊、陈威如。\n公司提醒投资者关注后续披露的正式业绩报告及相关信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675559888","title":"贝莱德在国药控股的H股好仓比例下降1.11%至9.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675559888","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675559888?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:18","pubTimestamp":1792142280,"startTime":"0","endTime":"0","summary":"南财智讯10月16日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于10月13日从10.34%下降至9.23%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610163898459414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610163898459414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK1500","01099","LU1115378108.SGD","LU0640798160.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675300784","title":"贝莱德在国药控股的H股好仓比例上升1.07%至10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675300784","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675300784?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:16","pubTimestamp":1792055760,"startTime":"0","endTime":"0","summary":"南财智讯10月15日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于10月12日从9.25%上升至10.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610153896987144.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610153896987144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1115378108.SGD","01099","BK1515","BK1197","LU0640798160.USD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675633097","title":"贝莱德在国药控股的H股好仓比例下降0.07%至8.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675633097","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675633097?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:19","pubTimestamp":1791883140,"startTime":"0","endTime":"0","summary":"南财智讯10月13日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于10月8日从9.06%下降至8.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610133894225424.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610133894225424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1115378108.SGD","01099","BK1515","BK1500","LU0640798160.USD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169143699","title":"国药控股：贝莱德增持，好仓比例升至9.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169143699","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169143699?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:22","pubTimestamp":1791364946,"startTime":"0","endTime":"0","summary":"贝莱德于2026年10月2日通过场外交易以取得股份保证权益的方式增持国药控股（01099）H股股份299.49万股，代价性质为非现金资产。该笔为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有国药控股好仓1.18亿股，占比8.82%；增持后持股量为1.21亿股，好仓比例升至9.05%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147355517","title":"国药控股9月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147355517","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147355517?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:36","pubTimestamp":1791362186,"startTime":"0","endTime":"0","summary":"2026年10月7日，国药控股（股票代码：01099）发布2026年9月股份变动月报表。公告显示，截至2026年9月30日，公司H股已发行总数为1,341,810,740股，内资股已发行总数为1,778,845,451股，与上个月保持一致。公司本月底法定/注册股本总额为3,120,656,191股，股本结构未发生变化。\n报告期内，国药控股无新增发行、回购或注销股份的记录，亦无挂牌香港联交所的香港预托证券、承诺发股权证、可换股票据或其他股份期权及转增安排。公司确认已满足香港联交所相关上市规则对公众持股量的要求，整体股本保持稳定。本次公告由公司秘书吴壹建签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672166367","title":"贝莱德在国药控股的H股好仓比例上升0.09%至9.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2672166367","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672166367?lang=zh_cn&edition=full","pubTime":"2026-10-02 18:04","pubTimestamp":1790935440,"startTime":"0","endTime":"0","summary":"南财智讯10月2日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于9月29日从8.99%上升至9.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610023888372227.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610023888372227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","LU0640798160.USD","BK1197","01099","BK1515","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132362755","title":"国药控股：贝莱德增持，好仓比例升至9.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132362755","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132362755?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:34","pubTimestamp":1790933692,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月29日通过取得股份保证权益的方式场外增持国药控股（01099）H股103.03万股。该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有国药控股好仓1.21亿股，占比8.99%；增持后持股量为1.22亿股，好仓比例升至9.08%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165151734","title":"国药控股：FMR LLC减持，好仓比例降至3.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165151734","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165151734?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:23","pubTimestamp":1790673821,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年9月24日以每股均价14.6610港元场外卖出国药控股股份2402.12万股，涉资约3.52亿港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。FMR LLC此次减持前持有国药控股好仓7762.30万股，占比5.78%；减持后持股量为5360.18万股，好仓比例降至3.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670405870","title":"FMR LLC减持国药控股(01099)73.24万股 每股作价约15.01港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670405870","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670405870?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:50","pubTimestamp":1790506221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月21日，FMR LLC减持国药控股(01099)73.24万股，每股作价15.0147港元，总金额约为1099.68万港元。减持后最新持股数目约为8041.37万股，最新持股比例为5.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","LU0640798160.USD","BK1197","01099","BK1515","LU1115378108.SGD","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670405877","title":"Lazard Asset Management LLC减持国药控股(01099)73.88万股 每股作价约15.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670405877","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670405877?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:44","pubTimestamp":1790505855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月21日，Lazard Asset Management LLC减持国药控股(01099)73.88万股，每股作价15.1035港元，总金额约为1115.85万港元。减持后最新持股数目约为1.88亿股，最新持股比例为13.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640798160.USD","01099","LU1115378108.SGD","EWH","BK1515","BK1500","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127783209","title":"国药控股：Lazard Asset Management LLC减持，好仓比例降至13.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127783209","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127783209?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:42","pubTimestamp":1790329332,"startTime":"0","endTime":"0","summary":"Lazard Asset Management LLC于2026年9月21日在联交所场内以每股均价15.1035港元卖出国药控股（01099）73.88万股，涉资约1115.85万港元，属场内主动交易，即在二级市场直接买卖股份。Lazard Asset Management LLC此次减持前持有国药控股好仓1.88亿股，占比14.04%；减持后持股量为1.88亿股，好仓比例降至13.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132051614","title":"国药控股：FMR LLC减持，好仓比例降至5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132051614","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132051614?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:25","pubTimestamp":1790328312,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年9月21日在联交所场内以每股均价15.0147港元卖出国药控股（01099）股份73.24万股，涉资约1099.68万港元，属场内主动交易，即在二级市场直接买卖股份。FMR LLC此次减持前持有国药控股好仓8114.61万股，占比6.05%；减持后持股量为8041.37万股，好仓比例降至5.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0233},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1742},{"period":"1year","weight":-0.1367},{"period":"ytd","weight":-0.1691}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004652},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029404},{"month":3,"riseRate":0.470588,"avgChangeRate":0.00701},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016475},{"month":5,"riseRate":0.588235,"avgChangeRate":-0.009205},{"month":6,"riseRate":0.411765,"avgChangeRate":-0.006214},{"month":7,"riseRate":0.529412,"avgChangeRate":-0.008781},{"month":8,"riseRate":0.411765,"avgChangeRate":0.005041},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.012951},{"month":10,"riseRate":0.666667,"avgChangeRate":0.041839},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.00729},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004119}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}